Literature DB >> 21567908

GM2 gangliosidosis in Saudi Arabia: multiple mutations and considerations for future carrier screening.

Namik Kaya1, Mohammad Al-Owain, Nada Abudheim, Jawaher Al-Zahrani, Dilek Colak, Moeen Al-Sayed, Aysel Milanlioglu, Pinar T Ozand, Fowzan S Alkuraya.   

Abstract

The GM2 gangliosidose, Tay-Sachs and Sandhoff diseases, are a class of lysosomal storage diseases in which relentless neurodegeneration results in devastating neurological disability and premature death. Primary prevention is the most effective intervention since no effective therapy is currently available. An extremely successful model for the prevention of GM2 gangliosidosis in the Ashkenazi Jewish community is largely attributable to the very limited number of founder mutations in that population. Consistent with our previous observation of allelic heterogeneity in consanguineous populations, we show here that these diseases are largely caused by private mutations which present a major obstacle in replicating the Ashkenazi success story. Alternative solutions are proposed which can also be implemented for other autosomal recessive diseases in our population.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567908     DOI: 10.1002/ajmg.a.33932

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  Clinical, biochemical and mutation profile in Indian patients with Sandhoff disease.

Authors:  Parag M Tamhankar; Mehul Mistri; Pratima Kondurkar; Daksha Sanghavi; Jayesh Sheth
Journal:  J Hum Genet       Date:  2015-11-19       Impact factor: 3.172

2.  Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates.

Authors:  Jagdeep S Walia; Naderah Altaleb; Alexander Bello; Christa Kruck; Matthew C LaFave; Gaurav K Varshney; Shawn M Burgess; Biswajit Chowdhury; David Hurlbut; Richard Hemming; Gary P Kobinger; Barbara Triggs-Raine
Journal:  Mol Ther       Date:  2014-12-17       Impact factor: 11.454

3.  Incidence and carrier frequency of Sandhoff disease in Saskatchewan determined using a novel substrate with detection by tandem mass spectrometry and molecular genetic analysis.

Authors:  Braden Fitterer; Patricia Hall; Nick Antonishyn; Rajagopal Desikan; Michael Gelb; Denis Lehotay
Journal:  Mol Genet Metab       Date:  2014-01-13       Impact factor: 4.797

4.  Three novel mutations in Iranian patients with Tay-Sachs disease.

Authors:  Solmaz Jamali; Nasim Eskandari; Omid Aryani; Shadab Salehpour; Talieh Zaman; Behnam Kamalidehghan; Massoud Houshmand
Journal:  Iran Biomed J       Date:  2014

5.  Genetics and genomic medicine in Saudi Arabia.

Authors:  Fowzan S Alkuraya
Journal:  Mol Genet Genomic Med       Date:  2014-07-30       Impact factor: 2.183

6.  Expanding the spectrum of HEXA mutations in Indian patients with Tay-Sachs disease.

Authors:  Jayesh Sheth; Mehul Mistri; Chaitanya Datar; Umesh Kalane; Shekhar Patil; Mahesh Kamate; Harshuti Shah; Sheela Nampoothiri; Sarita Gupta; Frenny Sheth
Journal:  Mol Genet Metab Rep       Date:  2014-09-29

7.  Genetic testing of leukodystrophies unraveling extensive heterogeneity in a large cohort and report of five common diseases and 38 novel variants.

Authors:  Nejat Mahdieh; Mahdieh Soveizi; Ali Reza Tavasoli; Ali Rabbani; Mahmoud Reza Ashrafi; Alfried Kohlschütter; Bahareh Rabbani
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

8.  Sequence and copy number analyses of HEXB gene in patients affected by Sandhoff disease: functional characterization of 9 novel sequence variants.

Authors:  Stefania Zampieri; Silvia Cattarossi; Ana Maria Oller Ramirez; Camillo Rosano; Charles Marques Lourenco; Nadia Passon; Isabella Moroni; Graziella Uziel; Antonella Pettinari; Franco Stanzial; Raquel Dodelson de Kremer; Nydia Beatriz Azar; Filiz Hazan; Mirella Filocamo; Bruno Bembi; Andrea Dardis
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.